Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphoma [7]

Leukemia

Volumn 17, Issue 5, 2003, Pages 987-990

  Niitsu, N ^a   Okamoto, M ^b   Honma, Y ^c   Nakamine, H ^d   Tamaru, J I ^e   Nakamura, S ^f   Yoshino, T ^g   Higashihara, M ^a   Hirano, M ^b   Okabe Kado, J ^c  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; NUCLEOSIDE DIPHOSPHATE KINASE A; PREDNISOLONE; PROCARBAZINE; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER REGRESSION; CELL PROLIFERATION; CLINICAL FEATURE; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; LETTER; LYMPHOMA CELL LINE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; T CELL LYMPHOMA; T LYMPHOCYTE RECEPTOR GENE; TREATMENT OUTCOME;

EID: 0038188780     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402858     Document Type: Letter

References (8)

1. Okabe-Kado J, Kasukabe T, Hozumi H, Honma Y, Kimura N, Baba H et al. A new function of Nm23/NDP kinase as a differentiation inhibitory factor, which does not require its kinase activity. FEBS Lett 1995; 363: 311-315.
2. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999; 94: 3541-3550.
3. Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001; 97: 1202-1210.
4. Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U et al. Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma. Leukemia 2003; 17: 196-202.
5. Okabe-Kado J. Serum nm23-H1 protein as a prognostic factor in hematological malignancies. Leukemia Lymphoma 2002; 43: 859-867.
6. Willems R, Van Bockstaele DR, Landon F, Lenjou M, Nijs G, Snoeck H-W et al. Decrease in nucleoside diphosphate kinase expression during hematopoietic maturation. J Biol Chem 1998; 273: 13663-13668.
7. Freije JM, Lawrence JA, Hollingshead MG, De la Rosa A, Narayanan V, Grever M et al. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nat Med 1997; 3: 395-401.
8. Cipollini G, Berti A, Fiore L, Rainaldi G, Basolo F, Merlo G et al. Down-regulation of the nm23.h1 gene inhibits cell proliferation. Int J Cancer 1997; 73: 297-302.